A Case of Post-operative Recurrence ALK-positive Lung Cancer Accompanied by Liver Dysfunction and Drug Eruption Caused by Crizotinib But Not Alectinib-Reference-Cited by-同舟云学术

A Case of Post-operative Recurrence ALK-positive Lung Cancer Accompanied by Liver Dysfunction and Drug Eruption Caused by Crizotinib But Not Alectinib

Published:2016 Issue:5 Volume:56 Page:337-341
ISSN:0386-9628
Container-title:Haigan
language:en
Short-container-title:JJLC

Author:

Ishibashi Naoya¹,Abe Kotaro¹,Sato Nobuyuki¹

Affiliation:

1. Department of Thoracic Surgery, Aomori Prefectural Central Hospital

Publisher

Japan Lung Cancer Society

Subject

Pulmonary and Respiratory Medicine,Oncology

Link

https://www.jstage.jst.go.jp/article/haigan/56/5/56_337/_pdf

Reference13 articles.

1. 1. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448: 561-566.

2. 2. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693-1703.

3. 3. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012; 13: 1011-1019.

4. 4. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371: 2167-2177.

5. 6. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368: 2385-2394.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Crizotinib;Reactions Weekly;2017-01